{"entity":{"type":"insider","cik":"0001357397","url":"/insider/0001357397","json_url":"/insider/0001357397.json","name":"McBarron Paul","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":5,"n_filings":4,"first":"2008-05-23","last":"2023-12-26","span_basis":"filed_date"},"name_variants":[{"name":"McBarron Paul","source":"filing","n_filings":4,"first_seen":"2008-05-23","last_seen":"2023-12-26"}],"transactions":[{"id":8146644,"accession":"0001104659-23-129186","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-129186","line_url":"/filing/0001104659-23-129186#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357397","owner_name":"McBarron Paul","owner_display_name":"McBarron Paul","owner_url":"/insider/0001357397","role":"Director, Officer","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1886.0,"shares_display":"1,886","price_per_share":3.315,"price_display":"3.32","price_state":"stated","total_value":6252.09,"total_display":"6,252.09","total_whole":"6,252","shares_owned_after":33378.0,"shares_owned_after_display":"33,378","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-21","filed_date":"2023-12-26","scope":"insider"},{"id":5106742,"accession":"0001104659-13-043961","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-13-043961","line_url":"/filing/0001104659-13-043961","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357397","owner_name":"McBarron Paul","owner_display_name":"McBarron Paul","owner_url":"/insider/0001357397","role":"Director, Officer (EVP, Finance, CFO, COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Finance, CFO, COO","security_title":"Common Stock, $0.001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12948.0,"shares_display":"12,948","price_per_share":3.0284784136546183,"price_display":"3.03","price_state":"stated","total_value":39212.7385,"total_display":"39,212.74","total_whole":"39,213","shares_owned_after":65481.0,"shares_owned_after_display":"65,481","ownership_form":"D","is_10b5_1":null,"transaction_date":"2013-05-21","filed_date":"2013-05-22","scope":"insider","n_lines":2},{"id":8954089,"accession":"0001104659-11-053334","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-11-053334","line_url":"/filing/0001104659-11-053334#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357397","owner_name":"McBarron Paul","owner_display_name":"McBarron Paul","owner_url":"/insider/0001357397","role":"Director, Officer (EVP, Finance, CFO, COO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"EVP, Finance, CFO, COO","security_title":"Common Stock, $0.001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":12000.0,"shares_display":"12,000","price_per_share":0.5,"price_display":"0.50","price_state":"stated","total_value":6000.0,"total_display":"6,000.00","total_whole":"6,000","shares_owned_after":188054.0,"shares_owned_after_display":"188,054","ownership_form":"D","is_10b5_1":null,"transaction_date":"2011-09-23","filed_date":"2011-09-26","scope":"insider"},{"id":2555980,"accession":"0001005477-08-003627","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001005477-08-003627","line_url":"/filing/0001005477-08-003627#line-1","is_derivative":false,"issuer_cik":"0001130166","issuer_name":"Cyclacel Pharmaceuticals, Inc.","issuer_ticker":"CYCC","issuer_name_source":null,"issuer_url":"/issuer/0001130166","owner_cik":"0001357397","owner_name":"McBarron Paul","owner_display_name":"McBarron Paul","owner_url":"/insider/0001357397","role":"Director, Officer (E.V.P., Finance & C.O.O)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"E.V.P., Finance & C.O.O.","security_title":"Common Stock, par value $0.001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1950.0,"shares_display":"1,950","price_per_share":2.25,"price_display":"2.25","price_state":"stated","total_value":4387.5,"total_display":"4,387.50","total_whole":"4,388","shares_owned_after":76054.0,"shares_owned_after_display":"76,054","ownership_form":"D","is_10b5_1":null,"transaction_date":"2008-05-22","filed_date":"2008-05-23","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":5,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":5,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":5},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001130166","name":"Cyclacel Pharmaceuticals, Inc.","url":"/issuer/0001130166","role":"Director, Officer","n_filings":4,"first_seen":"2008-05-23","last_seen":"2023-12-26"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001357397","retrieved_at":"2026-08-22T18:36:51+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}